NYSE · ZTS

ZOETIS Inc.

$78.57 +$3.22 (+4.27%) 1D Market open

Key Metrics

$31.26B
Market cap
11.83×
P/E · TTM
$9.51B
Revenue · TTM
$2.64B
Net income
EPS · TTM $5.90
Dividend yield
Free cash flow $2.14B
Beta · 1Y 0.66
EBITDA · TTM $3.80B
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 30
    From its Feb 27 high, the share price fell 45%.

    Peak close $131.10 on Feb 27; trough close $71.86 on Jun 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -45%
  • May 7
    The stock moved -21.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 7

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$31.59B
Enterprise value$38.37B
Shares outstanding419.2M
52-wk range$71.47 – $160.48
Avg volume · 20D2.7M
Net cash −$7.10B
Book value / share$7.22
IndustryPharmaceutical Preparations
ExchangeNYSE
About ZOETIS Inc.
IPO dateFeb 1, 2013
Employees14500

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E11.83
P/S3.29
P/FCF14.64
EV/EBITDA10.11
EV/Sales4.03
Graham №$30.95

Profitability

Gross
Operating 34.8%
Net 27.8%
FCF 22.5%
ROE / ROIC 66.1% · 25.6%

Financial Health

Current ratio3.15
Quick ratio1.91
Debt / equity2.80
Debt / EBITDA 2.38
Net cash −$7.10B
Working capital$4.42B

Cash Flow · TTM

Operating CF $2.72B
Capex −$582.00M
Free cash flow $2.14B
Buybacks $3.40B
Dividends paid
Shareholder yield 10.9%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

4.6
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$30.95 vs $75.35
Trades 2.4× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings